305 related articles for article (PubMed ID: 17264951)
21. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
[TBL] [Abstract][Full Text] [Related]
22. [Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case].
Ojeda-Uribe M; Brunot A; Issler M
Rev Med Chil; 2005 Nov; 133(11):1349-54. PubMed ID: 16446859
[TBL] [Abstract][Full Text] [Related]
23. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.
Gómez-Almaguer D; Solano-Genesta M; Tarín-Arzaga L; Herrera-Garza JL; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Jaime-Pérez JC
Blood; 2010 Dec; 116(23):4783-5. PubMed ID: 20841509
[TBL] [Abstract][Full Text] [Related]
24. Long-term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adults.
Wieland I; Kentouche K; Jentzsch M; Lothschütz D; Graf N; Sykora KW
Pediatr Blood Cancer; 2015 May; 62(5):823-9. PubMed ID: 25623397
[TBL] [Abstract][Full Text] [Related]
25. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia.
Rossignol J; Michallet AS; Oberic L; Picard M; Garon A; Willekens C; Dulery R; Leleu X; Cazin B; Ysebaert L
Leukemia; 2011 Mar; 25(3):473-8. PubMed ID: 21127498
[TBL] [Abstract][Full Text] [Related]
26. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
[TBL] [Abstract][Full Text] [Related]
27. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.
Westwood JP; Webster H; McGuckin S; McDonald V; Machin SJ; Scully M
J Thromb Haemost; 2013 Mar; 11(3):481-90. PubMed ID: 23279219
[TBL] [Abstract][Full Text] [Related]
28. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
[TBL] [Abstract][Full Text] [Related]
29. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.
Laribi K; Bolle D; Ghnaya H; Sandu A; Besançon A; Denizon N; Truong C; Pineau-Vincent F; de Materre AB
Ann Hematol; 2016 Apr; 95(5):765-9. PubMed ID: 26858026
[TBL] [Abstract][Full Text] [Related]
30. Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
Stasi R
Semin Hematol; 2010 Apr; 47(2):170-9. PubMed ID: 20350664
[TBL] [Abstract][Full Text] [Related]
31. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
32. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
33. Expanded utilization of rituximab in paediatric cardiac transplant patients.
Kiskaddon AL; Landmesser K; Carapellucci J; Wisotzkey B; Asante-Korang A
J Clin Pharm Ther; 2021 Jun; 46(3):762-766. PubMed ID: 33393702
[TBL] [Abstract][Full Text] [Related]
34. A patient with mixed type Evans syndrome: efficacy of rituximab treatment.
Park CY; Chung CH
J Korean Med Sci; 2006 Dec; 21(6):1115-6. PubMed ID: 17179698
[TBL] [Abstract][Full Text] [Related]
35. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
Zhou LY; Zhang Z; Song LX; Gzhang X; Su JY; Li X; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):941-4. PubMed ID: 22931660
[TBL] [Abstract][Full Text] [Related]
36. [Rituximab instead of splenectomy in 4 children with chronic or refractory autoimmune haemolytic anaemia].
van Daalen ST; van Dijken PJ; Tamminga RY; Brons PP
Ned Tijdschr Geneeskd; 2005 Oct; 149(42):2350-4. PubMed ID: 16261716
[TBL] [Abstract][Full Text] [Related]
37. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
Olfat M; Silverman ED; Levy DM
Lupus; 2015 Aug; 24(9):966-72. PubMed ID: 25804672
[TBL] [Abstract][Full Text] [Related]
38. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature.
Ling HT; Field JJ; Blinder MA
Am J Hematol; 2009 Jul; 84(7):418-21. PubMed ID: 19507208
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.
Tun NM; Villani GM
J Thromb Thrombolysis; 2012 Oct; 34(3):347-59. PubMed ID: 22547089
[TBL] [Abstract][Full Text] [Related]
40. New treatment options for immune-mediated hematological disorders.
Dierickx D; De Rycke A; Vanderschueren S; Delannoy A
Eur J Intern Med; 2008 Dec; 19(8):579-86. PubMed ID: 19046722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]